Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2021; 18(1):216-225. doi:10.7150/ijms.51172 This issue Cite

Research Paper

The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study

Aleksandra Kołtuniuk✉, Joanna Rosińczuk

Department of Nervous System Diseases, Wroclaw Medical University, Wroclaw, Poland.

✉ Corresponding author: Dr. Aleksandra Kołtuniuk, Department of Nervous System Diseases, Wroclaw Medical University, Bartla 5, 51-618 Wroclaw, Poland. Tel: +48 71 784 18 39; Fax: +48 71 345 93 24; E-mail: aleksandra.koltuniukwroc.pl.

Citation:
Kołtuniuk A, Rosińczuk J. The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. Int J Med Sci 2021; 18(1):216-225. doi:10.7150/ijms.51172. https://www.medsci.org/v18p0216.htm
Other styles

File import instruction

Abstract

Emotional functioning is one of the factors affecting medication adherence in patients with multiple sclerosis (MS). Adherence to treatment is a very important element in the therapy of patients with MS and requires from them cooperation, positive emotional status and acceptance of illness. This study evaluated the role of depression, anxiety, and the acceptance of illness on adherence to disease-modifying therapies (DMT) in MS. A group of 226 MS patients was included. The Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale-Modified Version (HADS-M), the Acceptance of Illness Scale (AIS) and the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ) were used. It was shown that 41% of patients reported the symptoms of anxiety, 28% reported the symptoms of depression, and 63% were irritated and aggressive (HADS-M). Over 80% of patients accept their disease to varying degrees. There was a correlation between the results of HADS-M, BDI, and AIS and the domains of MS-TAQ. Analysis of the multiple-regression model showed that only being very satisfied with treatment positively affects adherence to DMT in MS patients. It has to be concluded that anxiety and depression have a significant negative impact on medication adherence in MS patients. However, MS patients with an increased acceptance of their illness have a higher rate of adherence to DMT. The emotional state of a patient is an important factor that can both positively and negatively affect their adherence and their resulting prognosis.

Keywords: multiple sclerosis, anxiety, depression, treatment adherence, illness acceptance, disease-modifying therapy

Citation styles

APA
Kołtuniuk, A., Rosińczuk, J. (2021). The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. International Journal of Medical Sciences, 18(1), 216-225. https://doi.org/10.7150/ijms.51172.

ACS
Kołtuniuk, A.; Rosińczuk, J. The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. Int. J. Med. Sci. 2021, 18 (1), 216-225. DOI: 10.7150/ijms.51172.

NLM
Kołtuniuk A, Rosińczuk J. The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. Int J Med Sci 2021; 18(1):216-225. doi:10.7150/ijms.51172. https://www.medsci.org/v18p0216.htm

CSE
Kołtuniuk A, Rosińczuk J. 2021. The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study. Int J Med Sci. 18(1):216-225.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use